• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
3/2009 - Repatriation Medical Authority
3/2009 - Repatriation Medical Authority

... For the purposes of this Statement of Principles: "a clinically significant psychiatric condition" means any Axis 1 or Axis II disorder of mental health that attracts a diagnosis under DSMIV-TR which is sufficient to warrant ongoing management, excluding drug-related disorders. The ongoing managemen ...
an extension of biopharmaceutics classification system
an extension of biopharmaceutics classification system

... controlling rate and extension of drug absorption thus BCS becomes a fundamental tool in drug development. The BCS was developed primarily in the context of immediate release (IR) solid oral dosage forms. BCS recommends method for classification according to dosage form dissolution along with the so ...
the use and abuse of drugs a handbook for health educators
the use and abuse of drugs a handbook for health educators

... drawbacks modern medicine could not function without the help of potentially dangerous drugs, and their use by the medical profession is increasing, particularly in the developed countries. Accompanying the increased use of such substances by the medical profession, is a growing tendency for the ord ...
Document
Document

...  Treatment duration of a minimum of 18-24 months after culture conversion  When possible, continue injectable for minimum six months (at least 4 months post-culture conversion)  Continue at least three oral drugs for full treatment duration ISTC TB Training Modules 2009 ...
Drugedrug interaction through molecular structure similarity analysis
Drugedrug interaction through molecular structure similarity analysis

... one of the drugs due to both drugs being metabolized by the same enzymes or due to competition for the same transporter protein. In order to verify whether the model is also capable of predicting the effect produced by the DDI, a random selection of DrugBank interactions was reviewed manually to det ...
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES AND
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES AND

... Niosomes formed have a number of morphologies and their permeability and stability properties can be altered by manipulating membrane characteristics by different additives. The mean size of niosomes is influenced by membrane composition such as Polyhedral niosomes formed by C16G2: solulan C24 in ra ...
1: clinical pharmacokinetics
1: clinical pharmacokinetics

... Interestingly, food affects absorption and first-pass metabolism in opposite ways. Food usually decreases the F of drugs that are poorly absorbed (e.g. F of atenolol decreases by 50%), but increases the F of drugs that are subject to high first-pass metabolism (e.g. F of metoprolol increases by 50%). ...
Pharmacology/Therapeutics II Block II Lectures
Pharmacology/Therapeutics II Block II Lectures

... • Many individuals are not treated with medications (drug free) – Self-help groups such as Narcotics Anonymous – Inpatient detoxification facilities/residential – Individual therapy rare largely due to sociodemographic characteristics of users – Dependence on prescription opioids presents a new chal ...
2015 DRUGS TO WATCH
2015 DRUGS TO WATCH

... Japan in September 2014, it is in the US market that the drug is set to achieve blockbuster status, where it is expected to become available in early 2015. The PD-1 immune checkpoint inhibitor Opdivo was approved in the US in late December 2014, three months ahead of its March 2015 PDUFA date, for u ...
8: Malignant disease and immunosuppression
8: Malignant disease and immunosuppression

... More than 50 cytotoxic drugs are used in the management of malignant disease, and the recommended doses and schedules vary according to the tumour type and regimen. Anticancer cytotoxic treatment should always be prescribed under the supervision of an oncology specialist. For recommendations regardi ...
Harvard-MIT Division of Health Sciences and Technology
Harvard-MIT Division of Health Sciences and Technology

... Valproic acid effective in generalized as well as focal epilepsy; particularly useful when several seizure types are present. • New anticonvulsants Because they are new, the clinical indications for these agents are not yet completely defined, and none are currently used as the first treatment ...
Drug Interactions with HCV medications
Drug Interactions with HCV medications

... Ergots: Potential for acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. Rizatriptan: Co administration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Eletriptan: CONTRAINDICATE ...
Biochemical Markers as Tools to Increase Efficiency in Drug
Biochemical Markers as Tools to Increase Efficiency in Drug

... be used as a surrogate marker for product efficacy. In clinical settings, ...
Therapeutic Drug Monitoring of Antiepileptic Drugs in the 21st Century
Therapeutic Drug Monitoring of Antiepileptic Drugs in the 21st Century

... distinguished. There can be either an indication for systematic TDM on a regular basis, or a need for initial adjustment up to finding the right dose, or solely an indication for “on-need” control when confronted with clinical issues such as treatment resistance, side effects, or drug interactions. ...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA

... Treatment-Naïve, Phase • PEG/RBV TE subjects are represented III trial (GS-US-334-0110) within the treatment-naïve population ...
JCleary revised CND-INCB-WHO
JCleary revised CND-INCB-WHO

... promoting adequate availability of internationally controlled licit drugs for medical and scientific purposes while preventing their diversion and abuse, the balance between adequate availability of these drugs and prevention of their diversion and abuse is at the core of the international drug cont ...
1 = Butorphanol or Torbutrol/Torbugesic is a synthetic
1 = Butorphanol or Torbutrol/Torbugesic is a synthetic

... This is a synthetic morphinan analgesic with narcotic agonist-antagonist activity. It is commonly used pre-, intra- and post-operatively, as it increases the well-being of an animal-patient after a painful operation. It exerts analgesic effects via the CNS (central nervous system), by acting on the ...
nderzko - Harvard DASH
nderzko - Harvard DASH

... status. From that time on, the FDA would give prescription status to a drug if ...
Essentials of Pharmaceutical Chemistry
Essentials of Pharmaceutical Chemistry

... drug molecules is the carboxyl group, which ionises as shown in Fig. 3.1. The anion formed by ionisation of the acid is stabilised by the process of resonance. Neither of the two conventional structures ([a] and [b]) of the carboxylate anion shown in Fig. 3.2 is correct. A double bond in C = O is mu ...
sulfonamides-part-1
sulfonamides-part-1

... Elion and Hitchings synthesized trimethoprim, which was a highly effective antibacterial agent. It inhibits folate biosynthesis at DHFR. Resistance to it may result from reduced susceptibility to the drug, or less commonly over-production of DHFR. Both humans and bacteria have DHFR, but trimethopr ...
Industrial Pharmacy II - Home|Faculty Members Websites|The
Industrial Pharmacy II - Home|Faculty Members Websites|The

...  Twist-off softgels (designed with a tag to be twisted or snipped off allowing access to the fill material, it is very useful for unit dosing of topical medication, inhalations, or for oral dosing of pediatric product).  Meltable softgels (patient friendly pessaries or suppositories). ...
MFA - asdera
MFA - asdera

... by utilizing a computational biostatistics platform (US 7,664,616), the first platform to identify genetic risk factors for complex diseases Disruption of Active Language Development (DALD) in toddlers developing Autism Spectrum Disorders (ASD) by childhood migraines causing them to • become non-ver ...
Inheritance and Drug Response - New England Journal of Medicine
Inheritance and Drug Response - New England Journal of Medicine

... eventually be found to have genetic variation. The accompanying article by Evans and McLeod4 expands on many of the themes introduced here. Once a drug is administered, it is absorbed and distributed to its site of action, where it interacts with targets (such as receptors and enzymes), undergoes me ...
Chronobiology: Pulsatile Drug Delivery System
Chronobiology: Pulsatile Drug Delivery System

... resultant pharmacodynamics and pharmacokinetics parameters. The significance of these daylight variations has not been over looked from the drug-delivery perspective and pharmaceutical scientists have displayed considerable ingenuity in the development of time delayed drug delivery system to address ...
Drug Discovery Strategies Today
Drug Discovery Strategies Today

... Top Flops 2011  Expensive pivotal trial failures and regulatory setbacks continued to plague industry in 2011.  Thirty-one drugs, for either an initial indication or a major new indication, faltered during the filing process or in Phase III trials. ...
< 1 ... 43 44 45 46 47 48 49 50 51 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report